EGFR (Ab-1070) Antibody

What is EGFR (Ab-1070) Antibody and what epitope does it recognize?

EGFR (Ab-1070) Antibody is a rabbit polyclonal antibody that detects Epidermal Growth Factor Receptor (EGFR), a 175 kDa receptor tyrosine kinase involved in cell growth and differentiation signaling. This antibody specifically recognizes the Ab-1070 epitope of EGFR, while phospho-EGFR (Ser1070) antibodies specifically detect EGFR only when phosphorylated at Serine 1070 . The antibody is supplied at a concentration of 1.0mg/mL in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide, and 50% glycerol .

What are the recommended applications and dilutions for EGFR (Ab-1070) Antibody?

The EGFR (Ab-1070) Antibody has been validated for multiple applications, with specific recommended dilutions for each technique:

These dilutions serve as starting points and may require optimization based on sample type and experimental conditions.

How does EGFR (Ab-1070) Antibody cross-reactivity with other species compare?

EGFR (Ab-1070) Antibody demonstrates cross-reactivity with human, mouse, and rat EGFR, making it versatile for comparative studies across these species . Additional predicted reactivity includes pig, bovine, sheep, and rabbit EGFR proteins . This cross-reactivity is valuable for researchers conducting translational studies or using animal models.

What is the optimal storage protocol for EGFR (Ab-1070) Antibody?

For maximum stability and activity retention of EGFR (Ab-1070) Antibody, researchers should follow these storage guidelines:

• Short-term storage (up to one month): 4°C is recommended for frequent use

• Long-term storage: -20°C is optimal

• Avoid repeated freeze-thaw cycles to maintain antibody integrity and performance

Some researchers aliquot the antibody to minimize freeze-thaw cycles when long-term storage is required.

How can researchers validate the specificity of EGFR (Ab-1070) Antibody in their experimental system?

To ensure experimental rigor, validate EGFR (Ab-1070) Antibody specificity through:

• Positive and negative control cell lines with known EGFR expression patterns

• EGFR knockdown/knockout validation using siRNA or CRISPR-Cas9 systems

• Peptide competition assays using the immunizing peptide

• Comparison with other validated EGFR antibodies recognizing different epitopes

• Western blotting to confirm detection of the expected 175 kDa band

• Immunoprecipitation followed by mass spectrometry analysis

Each new experimental system requires validation to ensure confidence in results.

What are the critical methodological considerations for Western blotting with EGFR (Ab-1070) Antibody?

For optimal Western blot results with EGFR (Ab-1070) Antibody:

• Use appropriate lysis buffers that preserve EGFR integrity (available commercially as part of ELISA kits)

• Include protease and phosphatase inhibitors in lysis buffers to prevent degradation and dephosphorylation

• Load adequate protein (typically 20-50 μg total protein)

• Use freshly prepared samples when possible

• Confirm detection of the predicted 175 kDa molecular weight band

• Consider gradient gels (4-12%) for better resolution of high molecular weight proteins

• Include positive control lysates such as A431 cells, which express high levels of EGFR

What is the difference between EGFR (Ab-1070) Antibody and phospho-EGFR (Ser1070) Antibody?

These antibodies serve complementary but distinct research purposes:

Using both antibodies in parallel experiments enables researchers to determine both total EGFR expression and the proportion activated through Ser1070 phosphorylation.

What is the biological significance of EGFR Ser1070 phosphorylation?

Serine 1070 phosphorylation represents an important regulatory mechanism for EGFR function:

• The phosphorylation status at Ser1070 can be inhibited by specific ADAM17 inhibitory antibodies like MEDI3622, which also inhibits phosphorylation at other sites including Y1086, Y845, and Y1173 .

• Phosphorylation at serine residues can modulate receptor activity differently than tyrosine phosphorylation

• Ser1070 phosphorylation may influence receptor internalization, degradation, or interaction with downstream signaling partners

• Its phosphorylation status provides insights into EGFR signaling dynamics in response to ligand stimulation or therapeutic intervention

Understanding this specific phosphorylation event contributes to a more complete picture of EGFR regulation.

How can phospho-EGFR (Ser1070) and total EGFR antibodies be used together in research?

Combined use of these antibodies offers several research advantages:

• Parallel Western blotting: Run duplicate blots or strip and reprobe to compare total vs. phosphorylated EGFR levels

• ELISA-based quantification: Specialized ELISA kits allow measurement of both phospho-EGFR (Ser1070) and total EGFR in cell lysates

• Treatment response studies: Monitor changes in phosphorylation:total EGFR ratio following drug treatment

• Immunofluorescence co-localization: Examine spatial distribution of phosphorylated vs. total EGFR

• Biomarker investigation: Evaluate whether phospho-Ser1070 status correlates with clinical outcomes or drug sensitivity

This dual approach provides richer information about EGFR biology than either antibody alone.

How can EGFR (Ab-1070) Antibody contribute to EGFR-targeted therapy research?

EGFR (Ab-1070) Antibody serves multiple functions in EGFR-targeted therapy research:

• Patient stratification research: May help identify patients likely to respond to EGFR-targeted therapies based on receptor expression levels

• Resistance mechanism studies: Enables monitoring of EGFR expression changes in resistant vs. sensitive cell lines

• Combination therapy evaluation: Helps assess EGFR status when testing novel combinations with established EGFR inhibitors

• Preclinical model validation: Confirms EGFR expression in patient-derived xenografts and cell line models

• Biomarker development: Contributes to research identifying predictive biomarkers for EGFR-targeted therapies

Recent research highlights the importance of EGFR expression levels in predicting response to tyrosine kinase inhibitors (TKIs) even in wild-type EGFR tumors .

What is the relationship between EGFR mutations, phosphorylation status, and antibody detection?

This complex relationship has important implications for research:

• EGFR mutations (particularly exon 19 deletions and L858R) can alter receptor conformation and phosphorylation patterns

• Mutant EGFR often shows increased basal phosphorylation at multiple sites compared to wild-type EGFR

• The epitope recognized by EGFR (Ab-1070) Antibody may be affected by certain mutations

• Phospho-specific antibodies may show different detection patterns in mutant vs. wild-type EGFR

• Ser1070 phosphorylation patterns may differ between EGFR-TKI sensitive and resistant cell lines

Researchers should include appropriate controls when studying mutant EGFR, such as cell lines with known mutations (PC9, HCC827, H3255) alongside wild-type lines (A549) .

What role does EGFR Ser1070 phosphorylation play in drug resistance mechanisms?

Emerging research suggests phosphorylation at Ser1070 may contribute to resistance mechanisms:

• Changes in Ser1070 phosphorylation have been observed alongside inhibition of EGFR phosphorylation at other sites (Y1086, Y845, Y1173) following treatment with MEDI3622, an ADAM17 inhibitor

• The phosphorylation status of EGFR can affect its interaction with downstream signaling proteins

• Serine phosphorylation may alter receptor trafficking and degradation, potentially affecting drug efficacy

• Combination approaches targeting both EGFR tyrosine and serine phosphorylation might overcome certain resistance mechanisms

• Monitoring Ser1070 phosphorylation status across sensitive and resistant cell lines may reveal new therapeutic opportunities

How can EGFR (Ab-1070) Antibody be used in multiplexed analysis with other antibodies?

For sophisticated signaling studies, EGFR (Ab-1070) Antibody can be used in multiplexed analysis:

• Multi-color immunofluorescence: Combine with antibodies against other signaling proteins (using antibodies raised in different host species)

• Phospho-protein arrays: Include alongside antibodies against various phosphorylated EGFR residues and downstream effectors

• Sequential immunoprecipitation: Use EGFR (Ab-1070) Antibody for initial precipitation followed by detection of interacting proteins

• Mass cytometry (CyTOF): When conjugated to metal isotopes, enables simultaneous detection of multiple epitopes in single cells

• Proximity ligation assays: Combine with antibodies against potential interaction partners to visualize protein complexes

Careful optimization of antibody concentrations and appropriate controls are essential for reliable multiplexed results.

What is the relationship between EGFR post-translational modifications and the detection by EGFR (Ab-1070) Antibody?

Post-translational modifications (PTMs) can influence antibody recognition:

• Methylation at Arg-1199 by PRMT5 stimulates phosphorylation at Tyr-1197 , which may indirectly affect Ab-1070 epitope accessibility

• Different PTMs may cause conformational changes that enhance or mask the Ab-1070 epitope

• Subcellular localization of EGFR, which can be influenced by PTMs, may affect antibody accessibility in certain applications

• Sample preparation methods may preserve or disrupt certain PTMs, affecting detection

Researchers should consider these factors when interpreting results, especially when comparing across different experimental conditions.

How can EGFR (Ab-1070) Antibody be used to study EGFR interaction with other ErbB family members?

EGFR (Ab-1070) Antibody facilitates investigation of EGFR heterodimerization:

• Co-immunoprecipitation: Pull down EGFR complexes and probe for other ErbB family members

• Proximity-based assays: Combine with antibodies against other ErbB receptors to detect dimers

• FRET/FLIM analysis: When appropriately labeled, can detect close association with other labeled receptors

• Immunofluorescence co-localization: Visualize spatial relationships between EGFR and other family members

• Crosslinking studies: Stabilize transient interactions before immunoprecipitation with EGFR (Ab-1070) Antibody

Understanding EGFR heterodimerization patterns is particularly important in cancer research, as these interactions influence both signaling outcomes and therapeutic responses .

What are common technical issues when working with EGFR (Ab-1070) Antibody and how can they be resolved?

Systematic optimization of each experimental step is key to reliable results.

How should researchers interpret EGFR (Ab-1070) Antibody results in the context of EGFR signaling?

Proper interpretation requires consideration of several factors:

• EGFR expression levels vary widely across tissue types and cancer models, with ubiquitous expression but higher levels in certain cancers

• Sensitivity to EGFR-targeted therapies correlates with mutation status rather than just protein expression in many contexts

• EGFR signaling depends on both expression levels and activation status (phosphorylation)

• Different isoforms exist, with isoform 2 being expressed in ovarian cancers

• EGFR signaling is modulated by interaction with multiple ligands including EGF, TGF-α, amphiregulin, betacellulin, and others

Relating antibody-based EGFR detection to functional outcomes requires comprehensive experimental design that accounts for these complexities.

What reference standards should be used when working with EGFR (Ab-1070) Antibody?

For experimental validation, incorporate these reference standards:

• Positive control cell lines: A431 (high EGFR expression), BID007 (EGFR A763_Y764insFQEA mutation), PC9 (exon 19 deletion), HCC827 (exon 19 deletion), H3255 (L858R mutation)

• Negative control: Cell lines with low/no EGFR expression or EGFR-knockout models

• Phosphorylation controls: EGF-stimulated cells (positive) and serum-starved cells (negative) for phospho-specific detection

• Molecular weight markers: Confirm the expected 175 kDa (or 134 kDa depending on glycosylation status) band for EGFR

• Isotype control antibodies: For immunostaining applications to assess non-specific binding

Including appropriate controls enhances confidence in experimental results and facilitates troubleshooting.

How is EGFR (Ab-1070) Antibody contributing to research on novel EGFR-targeted therapeutics?

EGFR (Ab-1070) Antibody supports development of next-generation therapies:

• Evaluation of bispecific antibodies targeting EGFR and other tumor antigens

• Research on antibody-drug conjugates (ADCs) that deliver cytotoxic payloads to EGFR-expressing cells

• Development of EGFR-targeted vaccines

• Testing of fourth-generation EGFR TKIs

• pH-dependent antibodies with improved tumor selectivity

These emerging approaches aim to overcome limitations of current EGFR-targeted therapies, particularly resistance mechanisms.

What new methodologies are being developed for measuring EGFR Ser1070 phosphorylation?

Recent technological advances include:

• ELISA-based quantification: Sandwich ELISA kits specifically for phospho-EGFR (Ser1070) measurement in cell lysates

• Phosphoproteomic approaches: Mass spectrometry-based detection of Ser1070 phosphorylation alongside other modifications

• Cell-based assays: High-throughput screening platforms to identify modulators of Ser1070 phosphorylation

• Proximity-based detection: Methods to visualize Ser1070 phosphorylation in intact cells

• Computational modeling: Prediction of how Ser1070 phosphorylation affects EGFR structure and function

These methods enhance our ability to understand the dynamic regulation of EGFR through serine phosphorylation.

How does current research on EGFR mutations inform the use of EGFR (Ab-1070) Antibody in clinical research?

Ongoing EGFR mutation research has implications for antibody-based studies:

• Bibliometric analysis shows increasing research on resistance to EGFR-TKIs, highlighting the need for comprehensive antibody tools

• Different EGFR mutations show "intricate differences" in biology and TKI response, requiring careful antibody selection and validation

• Beyond common mutations, rare variants like A763_Y764insFQEA show unique signaling properties that can be studied with appropriate antibodies

• Combination approaches targeting both EGFR and other pathways necessitate multiplexed antibody analysis

• Translational research increasingly requires antibodies that work across multiple applications (IHC, IF, WB) for comprehensive characterization

As EGFR research evolves, the applications of EGFR (Ab-1070) Antibody will continue to expand in both basic and translational research contexts.